Knight Therapeutics Inc. (OTCMKTS:KHTRF) Sees Significant Increase in Short Interest

Knight Therapeutics Inc. (OTCMKTS:KHTRF) saw a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 560,000 shares, an increase of 62.2% from the October 31st total of 345,200 shares. Based on an average daily trading volume, of 14,900 shares, the short-interest ratio is presently 37.6 days.

Knight Therapeutics Stock Performance

Shares of OTCMKTS KHTRF opened at $3.73 on Friday. Knight Therapeutics has a 12-month low of $3.65 and a 12-month high of $4.55. The stock has a 50 day simple moving average of $4.06 and a 200-day simple moving average of $4.15.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.